Defining clinical failure for salvage studies

References

• Herbrecht R, Denning D W, Patterson T F, et al. Invasive fungal infections group of the European Organisation for Research and Treatment of Cancer and the Global Aspergillus Study Group. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408–415
   PubMed Web of Science ®Google Scholar
• Mills W, Chopra R, Linch D C, et al. Liposomal amphotericin B in the treatment of fungal infections in neutropenic patients: a single-centre experience of 133 episodes in 116 patients. Br J Haematol 1994; 86: 754–760
   PubMed Web of Science ®Google Scholar
• Bowden R, Chandrasekar P, White M H, et al. A double-blind, randomized, controlled trial of amphotericin B colloidal dispersion versus amphotericin B for treatment of invasive aspergillosis in immunocompromised patients. Clin Infect Dis 2002; 35: 359–366
   PubMed Web of Science ®Google Scholar
• Cornely O A, Maertens J, Bresnik M, , et al. Liposomal amphotericin B as initial therapy for invasive filamentous fungal infections: A randomized, prospective trial of a high loading regimen vs. standard dosing (AmBiLoad Trial). Blood 2005; 106, Abstr #3222.
   PubMed Web of Science ®Google Scholar
• Ellis M, Spence D, de Pauw B, et al. An EORTC international multicenter randomized trial (EORTC number 19923) comparing two dosages of liposomal amphotericin B for treatment of invasive aspergillosis. Clin Infect Dis 1998; 27: 1406–1412
   PubMed Web of Science ®Google Scholar
• Leenders A C A P, Daenen S, Jansen R L H, et al. Liposomal amphotericin B compared with amphotericin B deoxycholate in the treatment of documented and suspected neutropenia-associated invasive fungal infections. Br J Haematol 1998; 103: 205–212
   PubMed Web of Science ®Google Scholar
• Walsh T J, Teppler H, Donowitz G R, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med 2004; 351: 1391–1402
   PubMed Web of Science ®Google Scholar
• Lass-Flörl C, Griff K, Mayr A, et al. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience. Br J Haematol 2005; 131: 201–207
   PubMed Web of Science ®Google Scholar
• Paterson P J, Seaton S, Prentice H G, et al. Treatment failure in invasive aspergillosis: susceptibility of deep tissue isolates following treatment with amphotericin B. J Antimicrob Chemother 2003; 52: 873–876
   PubMed Web of Science ®Google Scholar
• Denning D W, Venkateswarlu K, Oakley K L, et al. Itraconazole resistance in Aspergillus fumigatus. Antimicrob Agents Chemother 1997; 41: 1364–1368
   PubMed Web of Science ®Google Scholar
• Patterson T F, Boucher H W, Herbrecht R, et al. European Organization for Research and Treatment of Cancer (EORTC) Invasive Fungal Infections Group (IFIG); Pfizer Global Aspergillus Study Group. Strategy of following voriconazole versus amphotericin B therapy with other licensed antifungal therapy for primary treatment of invasive aspergillosis: impact of other therapies on outcome. Clin Infect Dis 2005; 41: 1448–1452
   PubMed Web of Science ®Google Scholar
• Maertens J, Raad I, Petrikkos G, et al. Caspofungin Salvage Aspergillosis Study Group. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis 2004; 39: 1563–1571
   PubMed Web of Science ®Google Scholar
• Caillot D, Couaillier J F, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol 2001; 19: 253–259
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Groll A H, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12–23
   PubMed Web of Science ®Google Scholar
• Pagano L, Ricci P, Nosari A, et al. Fatal haemoptysis in pulmonary filamentous mycosis: an underevaluated cause of death in patients with acute leukaemia in haematological complete remission. A retrospective study and review of the literature. Gimema Infection Program (Gruppo Italiano Malattie Ematologiche dell'Adulto). Br J Haematol 1995; 89: 500–505
   PubMedGoogle Scholar
• Sulahian A, Touratier S, Ribaud P. False positive test for Aspergillus antigenemia related to concomitant administration of piperacillin and tazobactam. N Engl J Med 2003; 349: 2366–2367
   PubMed Web of Science ®Google Scholar
• Viscoli C, Machetti M, Cappellano P, et al. False-positive galactomannan platelia Aspergillus test results for patients receiving piperacillin-tazobactam. Clin Infect Dis 2004; 38: 913–916
   PubMed Web of Science ®Google Scholar
• Groll A H, Gea-Banacloche J C, Glasmacher A, et al. Clinical pharmacology of antifungal compounds. Infect Dis Clin North Am 2003; 17: 159–191
   PubMed Web of Science ®Google Scholar